These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7553685)

  • 1. Immunotherapy of human colon cancer by antibody-targeted superantigens.
    Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
    Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
    Lando PA; Dohlsten M; Ohlsson L; Kalland T
    Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
    Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
    Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
    Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
    Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
    Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
    Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
    Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
    Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
    J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies and superantigens: a novel therapeutic approach.
    Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
    Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
    Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
    Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered superantigens as tolerable antitumor agents.
    Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells.
    Dohlsten M; Sundstedt A; Björklund M; Hedlund G; Kalland T
    Int J Cancer; 1993 May; 54(3):482-8. PubMed ID: 8509223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.
    Nielsen SE; Zeuthen J; Lund B; Persson B; Alenfall J; Hansen HH
    J Immunother; 2000 Jan; 23(1):146-53. PubMed ID: 10687147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
    Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
    J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted superantigens for immunotherapy of haematopoietic tumours.
    Tötterman TH; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M
    Vox Sang; 1998; 74 Suppl 2():483-7. PubMed ID: 9704486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
    Lando PA; Dohlsten M; Hedlund G; Akerblom E; Kalland T
    Cancer Immunol Immunother; 1993; 36(4):223-8. PubMed ID: 8439985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response during tumor therapy with antibody-superantigen fusion proteins.
    Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
    Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.